Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.

Medicine (Baltimore) · 2016 · PMC4718285 · PMID 26765459

Europe PMC DOI

hedged sentences

0.0590

closest p · 1.2× alpha

0.6450

boldest claim

The sentences

did not reach statistical significanceP = 0.059so close (0.05 < p ≤ 0.1)

BAP1 IHC positive ICCs demonstrated worse median survival, 24.87 months (95% CI, 18.73–31.01 months), compared with BAP1 IHC negative cases, 40.80 months (95% CI, 28.14–53.46 months), but this did not reach statistical significance ( P = 0.059).

also in 111,027 other papers

a strong trendP = 0.059so close (0.05 < p ≤ 0.1)

BAP1 loss predicted a strong trend toward improved median survival of 40.80 months (95% CI, 28.14–53.46) versus 24.87 months (95% CI, 18.73–31.01), P = 0.059).

also in 5,725 other papers

just failed to reach statistical significanceP = 0.059so close (0.05 < p ≤ 0.1)

There was also a strong trend toward prolonged survival in BAP1 IHC negative cases (median survival of 40.80 months (95% CI 28.14–53.46 months) versus 24.87 months (95% CI 18.73–31.01 months) for BAP1 IHC positive cases, but this just failed to reach statistical significance ( P = 0.059).

also in 203 other papers

a slight trendP = 0.645not close (p > 0.1)

Multivariate analysis in a model which included age, sex, BAP1 status, tumor stage, tumor grade, lymphatic invasion, vascular invasion, and tumor size (Table 2 ) found only a slight trend toward increased survival associated with loss of BAP1 expression, which was not statistically significant (HR 0.89; 95% CI, 0.55–1.45; P = 0.645).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.